Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Predictive cluster level surrogacy in the presence of interference.

Gabriel EE, Follmann DA.

Biostatistics. 2018 Sep 21. doi: 10.1093/biostatistics/kxy050. [Epub ahead of print]

PMID:
30247535
2.

Causal estimands and confidence intervals associated with Wilcoxon-Mann-Whitney tests in randomized experiments.

Fay MP, Brittain EH, Shih JH, Follmann DA, Gabriel EE.

Stat Med. 2018 Sep 10;37(20):2923-2937. doi: 10.1002/sim.7799. Epub 2018 May 17.

3.

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC, Martin MA.

Nat Med. 2018 May;24(5):610-616. doi: 10.1038/s41591-018-0001-2. Epub 2018 Apr 16.

4.

Streptococcal group A, C and G pharyngitis in school children: a prospective cohort study in Southern India.

Jose JJM, Brahmadathan KN, Abraham VJ, Huang CY, Morens D, Hoe NP, Follmann DA, Krause RM.

Epidemiol Infect. 2018 May;146(7):848-853. doi: 10.1017/S095026881800064X. Epub 2018 Apr 4.

5.

A boundary-optimized rejection region test for the two-sample binomial problem.

Gabriel EE, Nason M, Fay MP, Follmann DA.

Stat Med. 2018 Mar 30;37(7):1047-1058. doi: 10.1002/sim.7579. Epub 2017 Dec 26.

PMID:
29280170
6.

Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals.

Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, Evans HL, Rhee C, Suffredini AF, Hooper DC, Follmann DA, Bulger EM, Danner RL.

Clin Infect Dis. 2017 Apr 1;64(7):877-885. doi: 10.1093/cid/ciw871.

7.

Non-inferiority tests for anti-infective drugs using control group quantiles.

Fay MP, Follmann DA.

Clin Trials. 2016 Dec;13(6):632-640. Epub 2016 Jul 17.

8.

Recurrent event data analysis with intermittently observed time-varying covariates.

Li S, Sun Y, Huang CY, Follmann DA, Krause R.

Stat Med. 2016 Aug 15;35(18):3049-65. doi: 10.1002/sim.6901. Epub 2016 Feb 16.

9.

Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges.

Kennedy SB, Neaton JD, Lane HC, Kieh MW, Massaquoi MB, Touchette NA, Nason MC, Follmann DA, Boley FK, Johnson MP, Larson G, Kateh FN, Nyenswah TG.

Clin Trials. 2016 Feb;13(1):49-56. doi: 10.1177/1740774515621037. Epub 2016 Jan 14.

PMID:
26768572
10.

CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types.

Migueles SA, Mendoza D, Zimmerman MG, Martins KM, Toulmin SA, Kelly EP, Peterson BA, Johnson SA, Galson E, Poropatich KO, Patamawenu A, Imamichi H, Ober A, Rehm CA, Jones S, Hallahan CW, Follmann DA, Connors M.

EBioMedicine. 2014 Dec 22;2(1):46-58. doi: 10.1016/j.ebiom.2014.12.009. eCollection 2015 Jan.

11.

Estimation of mean response via effective balancing score.

Hu Z, Follmann DA, Wang N.

Biometrika. 2014 Sep;101(3):613-624.

12.

Vaccine design via nonnegative lasso-based variable selection.

Hu Z, Follmann DA, Miura K.

Stat Med. 2015 May 10;34(10):1791-8. doi: 10.1002/sim.6452. Epub 2015 Feb 2.

13.

A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, Golding H, Neuzil KM, Subbarao K.

J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021.

14.

Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO.

Sci Transl Med. 2012 Sep 12;4(151):151ra126. doi: 10.1126/scitranslmed.3004073.

15.

A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.

Brittain EH, Fay MP, Follmann DA.

Biostatistics. 2012 Sep;13(4):637-49. doi: 10.1093/biostatistics/kxs006. Epub 2012 Mar 30.

16.

A maximum pseudo-profile likelihood estimator for the Cox model under length-biased sampling.

Huang CY, Qin J, Follmann DA.

Biometrika. 2012 Mar;99(1):199-210. Epub 2012 Jan 27.

17.

Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS.

De Pascalis R, Chou AY, Bosio CM, Huang CY, Follmann DA, Elkins KL.

PLoS Pathog. 2012 Jan;8(1):e1002494. doi: 10.1371/journal.ppat.1002494. Epub 2012 Jan 19.

18.

Dimension reduced kernel estimation for distribution function with incomplete data.

Hu Z, Follmann DA, Qin J.

J Stat Plan Inference. 2011 Sep;141(9):3084-3093.

19.

Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.

Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, Highbarger HC, Somaroo H, Sangweni P, Follmann DA, Pau AK; Phidisa II Study Team.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):304-8. doi: 10.1097/QAI.0b013e3182278c29.

20.

Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

Dlamini JN, Hu Z, Somaroo H, Highbarger HC, Follmann DA, Dewar RL, Pau AK.

Pharmacotherapy. 2011 Feb;31(2):158-63. doi: 10.1592/phco.31.2.158.

21.

Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.

Ho J, Moir S, Wang W, Posada JG, Gu W, Rehman MT, Dewar R, Kovacs C, Sneller MC, Chun TW, Follmann DA, Fauci AS.

AIDS. 2011 Jan 28;25(3):295-302. doi: 10.1097/QAD.0b013e328342328b.

22.

A model checking method for the proportional hazards model with recurrent gap time data.

Huang CY, Luo X, Follmann DA.

Biostatistics. 2011 Jul;12(3):535-47. doi: 10.1093/biostatistics/kxq071. Epub 2010 Dec 6.

23.

Semiparametric dimension reduction estimation for mean response with missing data.

Hu Z, Follmann DA, Qin J.

Biometrika. 2010 Jun;97(2):305-319. Epub 2010 Apr 23.

24.

Interferon-alpha produces significant decreases in HIV load.

Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC.

J Interferon Cytokine Res. 2010 Jul;30(7):461-4. doi: 10.1089/jir.2009.0090.

25.

Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.

Willey R, Nason MC, Nishimura Y, Follmann DA, Martin MA.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):89-98. doi: 10.1089/aid.2009.0144.

26.

Immunologic and virologic events in early HIV infection predict subsequent rate of progression.

Ganesan A, Chattopadhyay PK, Brodie TM, Qin J, Gu W, Mascola JR, Michael NL, Follmann DA, Roederer M; Infectious Disease Clinical Research Program HIV Working Group.

J Infect Dis. 2010 Jan 15;201(2):272-84. doi: 10.1086/649430.

27.

Empirical Likelihood-Based Estimation of the Treatment Effect in a Pretest-Posttest Study.

Huang CY, Qin J, Follmann DA.

J Am Stat Assoc. 2008 Sep 1;103(483):1270-1280.

28.

The effect of continuous versus pericycle antiretroviral therapy on IL-2 responsiveness.

Healey LM, Hahn BK, Rehm CA, Adelsberger J, Qin J, Follmann DA, Tavel J, Kovacs JA, Sereti I, Davey RT Jr.

J Interferon Cytokine Res. 2008 Jul;28(7):455-62. doi: 10.1089/jir.2007.0120.

29.
30.
31.

Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia.

Kim YJ, Kumaraswami V, Choi E, Mu J, Follmann DA, Zimmerman P, Nutman TB.

Am J Trop Med Hyg. 2005 Jul;73(1):125-30.

PMID:
16014847
32.

The accelerated biased coin up-and-down design in phase I trials.

Stylianou M, Follmann DA.

J Biopharm Stat. 2004 Feb;14(1):249-60.

PMID:
15027512
33.

Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates.

Kuramoto K, Follmann DA, Hematti P, Sellers S, Agricola BA, Metzger ME, Donahue RE, von Kalle C, Dunbar CE.

Blood. 2004 Jun 1;103(11):4070-7. Epub 2004 Feb 12.

PMID:
14962906
34.

Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection.

Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, Masur H, Follmann DA, Lane HC, Davey RT Jr.

Blood. 2004 May 1;103(9):3282-6. Epub 2004 Jan 15.

PMID:
14726376
35.

Parametric and semiparametric approaches to testing for seasonal trend in serial count data.

Hunsberger S, Albert PS, Follmann DA, Suh E.

Biostatistics. 2002 Jun;3(2):289-98.

PMID:
12933619
36.

Comparing HLA antigen frequencies between two groups of patients.

Follmann DA.

Stat Med. 2003 Jun 30;22(12):1999-2013.

PMID:
12802818
37.

Regression analysis based on pairwise ordering of patients' clinical histories.

Follmann DA.

Stat Med. 2002 Nov 30;21(22):3353-67.

PMID:
12407677
38.

A latent autoregressive model for longitudinal binary data subject to informative missingness.

Albert PS, Follmann DA, Wang SA, Suh EB.

Biometrics. 2002 Sep;58(3):631-42.

PMID:
12229998
39.

Bayesian monitoring of event rates with censored data.

Follmann DA, Albert PS.

Biometrics. 1999 Jun;55(2):603-7. Erratum in: Biometrics. 2013 Jun;69(2):556.

PMID:
11318221
40.

Repeated probit regression when covariates are measured with error.

Follmann DA, Hunsberger SA, Albert PS.

Biometrics. 1999 Jun;55(2):403-9.

PMID:
11318193
41.
42.

A multivariate test of interaction for use in clinical trials.

Follmann DA, Proschan MA.

Biometrics. 1999 Dec;55(4):1151-5.

PMID:
11315061
43.
44.

Valid inference in random effects meta-analysis.

Follmann DA, Proschan MA.

Biometrics. 1999 Sep;55(3):732-7.

PMID:
11315000
45.

Essentials of randomized clinical trials.

Follmann DA, Schron EB.

Pacing Clin Electrophysiol. 2001 Feb;24(2):254-9. Review. No abstract available.

PMID:
11270712
46.

Testing for treatment and interaction effects in semi-parametric analysis of covariance.

Hunsberger S, Follmann DA.

Stat Med. 2001 Jan 15;20(1):1-19.

PMID:
11135344
47.

Modeling repeated count data subject to informative dropout.

Albert PS, Follmann DA.

Biometrics. 2000 Sep;56(3):667-77.

PMID:
10985201
48.

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ.

J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10.

PMID:
10902785
49.

A generalized estimating equation approach for modeling random length binary vector data.

Albert PS, Follmann DA, Barnhart HX.

Biometrics. 1997 Sep;53(3):1116-24.

PMID:
9290230
50.

Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.

Domanski MJ, Sloas MM, Follmann DA, Scalise PP 3rd, Tucker EE, Egan D, Pizzo PA.

J Pediatr. 1995 Jul;127(1):137-46.

PMID:
7608800

Supplemental Content

Loading ...
Support Center